Release of infectious virus and cytokines in nasopharyngeal swabs from individuals infected with non-alpha or alpha SARS-CoV-2 variants: an observational retrospective study

[1]  F. Rieux-Laucat,et al.  Distinct systemic and mucosal immune responses during acute SARS-CoV-2 infection , 2021, Nature Immunology.

[2]  I. Diamond,et al.  Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK , 2021, medRxiv.

[3]  E. Lau,et al.  Transmission dynamics and epidemiological characteristics of Delta variant infections in China , 2021, medRxiv.

[4]  Joshua B. Singer,et al.  Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study , 2021, The Lancet Infectious Diseases.

[5]  J. Pawlotsky,et al.  Performance of six rapid diagnostic tests for SARS-CoV-2 antigen detection and implications for practical use , 2021, Journal of Clinical Virology.

[6]  Haibo Zhang,et al.  Emerging SARS-CoV-2 variants of concern and potential intervention approaches , 2021, Critical Care.

[7]  F. Rey,et al.  Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization , 2021, Nature.

[8]  M. Malim,et al.  Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study , 2021, The Lancet Microbe.

[9]  J. Klingström,et al.  Shedding of infectious SARS-CoV-2 by hospitalized COVID-19 patients in relation to serum antibody responses , 2021, BMC Infectious Diseases.

[10]  P. Maes,et al.  Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters , 2021, EBioMedicine.

[11]  M. Singer,et al.  Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study , 2021, The Lancet Infectious Diseases.

[12]  A. Fontanet,et al.  SARS-CoV-2 infection in schools in a northern French city: a retrospective serological cohort study in an area of high transmission, France, January to April 2020 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  Daniel S. Chertow,et al.  SARS-CoV-2 infection of the oral cavity and saliva , 2021, Nature Medicine.

[14]  William T. Harvey,et al.  Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies , 2021, Nature.

[15]  A. Fontanet,et al.  Sex differences in the evolution of neutralizing antibodies to SARS-CoV-2 , 2021, The Journal of infectious diseases.

[16]  L. Leinwand,et al.  Just 2% of SARS-CoV-2-positive individuals carry 90% of the virus circulating in communities , 2021, medRxiv.

[17]  P. Calistri,et al.  Infection sustained by lineage B.1.1.7 of SARS-CoV-2 is characterised by longer persistence and higher viral RNA loads in nasopharyngeal swabs , 2021, International Journal of Infectious Diseases.

[18]  Carl A. B. Pearson,et al.  Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England , 2021, Science.

[19]  S. Kissler,et al.  Densely sampled viral trajectories suggest longer duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2 , 2021, medRxiv.

[20]  S. Atabani,et al.  S-variant SARS-CoV-2 lineage B1.1.7 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-qPCR , 2021, The Journal of infectious diseases.

[21]  H. Mouquet,et al.  Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies , 2021, Nature Medicine.

[22]  Naomi R. Waterlow,et al.  Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 , 2021, Nature.

[23]  Charles K. Cooper,et al.  Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  M. M. van der Eerden,et al.  Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) , 2021, Nature communications.

[25]  A. Pollock,et al.  Asymptomatic transmission of covid-19 , 2020, BMJ.

[26]  M. Cevik,et al.  SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis , 2020, The Lancet Microbe.

[27]  E. Fischer,et al.  Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer , 2020, Cell.

[28]  Benjamin J Cowling,et al.  Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong , 2020, Nature Medicine.

[29]  Y. Yazdanpanah,et al.  A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations , 2020, Science Translational Medicine.

[30]  Eric Song,et al.  Longitudinal analyses reveal immunological misfiring in severe COVID-19 , 2020, Nature.

[31]  Nguyen H. Tran,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial , 2020, The Lancet.

[32]  Sasikanth Manne,et al.  Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications , 2020, Science.

[33]  H. Mouquet,et al.  Syncytia formation by SARS‐CoV‐2‐infected cells , 2020, bioRxiv.

[34]  Nicolas Carlier,et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.

[35]  Patricia Harrington,et al.  SARS-CoV-2 detection, viral load and infectivity over the course of an infection , 2020, Journal of Infection.

[36]  P. V. Van Caeseele,et al.  Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples , 2020, Clinical Infectious Diseases.

[37]  A. Broom,et al.  SARS-CoV-2: The viral shedding vs infectivity dilemma , 2020, Infection, Disease & Health.

[38]  M. Merad,et al.  Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages , 2020, Nature Reviews Immunology.

[39]  D. Raoult,et al.  Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards , 2020, European Journal of Clinical Microbiology & Infectious Diseases.

[40]  Yongsheng Wu,et al.  Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study , 2020, The Lancet Infectious Diseases.

[41]  Anne Kimball,et al.  Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility , 2020, The New England journal of medicine.

[42]  T. C. I. team.  Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States , 2020 .

[43]  Catherine M. Brown,et al.  Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States , 2020, Nature Medicine.

[44]  P. Vollmar,et al.  Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.

[45]  O. Tsang,et al.  Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study , 2020, The Lancet Infectious Diseases.

[46]  Eric H. Y. Lau,et al.  Temporal dynamics in viral shedding and transmissibility of COVID-19 , 2020, Nature Medicine.

[47]  T. Heidmann,et al.  IFITM proteins inhibit placental syncytiotrophoblast formation and promote fetal demise , 2019, Science.

[48]  F. Rieux-Laucat,et al.  Type I interferon-mediated autoinflammation due to DNase II deficiency , 2017, Nature Communications.

[49]  Investigation of novel SARS-COV-2 variant Variant of Concern 202012/01 , 2020 .